(slxn - SILEXION THERAPEUTICS CORP)

company profile

Silexion Therapeutics Corp, a clinical-stage biotechnology company, discovers and develops RNA interference (RNAi) therapies for KRAS-driven cancers. Its products comprise SIL204 second-generation small interfering RNA (siRNA) undergoing phase 2/3 clinical evaluation for pancreatic cancer and silence mutant KRAS oncogene expression. The company was founded in 2008 and is headquartered in Ramat Gan, Israel.

Silexion Therapeutics (slxn) is trading at 1.76

Open Price
1.98
Previous close
1.76
Previous close
1.76
P/E Ratio
0
Sector
Health Care
Shares outstanding
649528
Primary exchange
NASDAQ-NMS
ISIN
KYG1281K1638